Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Needham Cuts Edwards Lifesciences to Hold

From Standard & Poor's Equity Research

Needham downgraded Edwards Lifesciences (EW) to hold from buy, after the company posted quarterly results.

Analyst Clay Wilson says the company's heart valve business growth slowed to 2% in the second quarter, down from 7% in the first, and 15% over 2005. With the heart valve franchise accounting for 48% of total revenues, he believes this slowing merits attention. He says 52 cents second quarter pro forma EPS was slightly above consensus, but slightly below his 55 cents estimate. He cut his $2.21 2006 earnings per share (EPS) estimate to $2.00. He believes that heart valve growth levels over the next two quarters will be very important indicators that will merit close monitoring. He downgrades and discontinues his price target at this time.

blog comments powered by Disqus